.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,345,663

« Back to Dashboard

Details for Patent: 9,345,663

Title:Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
Inventor(s): Montgomery; Alan B. (Medina, WA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Apr 30, 2014
Application Number:14/266,096
Claims:1. A process for preparation of aztreonam lysinate for inhalation comprising manufacturing a bulk solution of aztreonam lysinate by addition of .alpha.-aztreonam to a lysine solution or by addition of a lysine solution to .alpha.-aztreonam.

2. The process according to claim 1 comprising addition of .alpha.-aztreonam to a lysine solution.

3. The process according to claim 1 comprising addition of a lysine solution to an .alpha.-aztreonam solution or slurry.

4. The process according to claim 3 comprising titration of a lysine solution into an .alpha.-aztreonam solution or slurry.

5. The process according to claim 1 during which process conversion of .alpha.-aztreonam to .beta.-aztreonam is avoided.

6. The process according to claim 2 wherein the aztreonam lysinate is generated with an impurity level less than 0.1%.

7. The process according to claim 3 wherein the aztreonam lysinate is generated with an impurity level less than 0.1%.

8. The process according to claim 1 wherein the aztreonam lysinate formed is kept within a pH lower than 6.

9. The process according to claim 3 wherein the .alpha.-aztreonam solution or slurry and bulk solution of aztreonam lysinate have a pH between 4.2 and 7.

10. The process according to claim 9 wherein the pH of the .alpha.-aztreonam solution or slurry and bulk solution of aztreonam lysinate is between 4.6 and 4.8.

11. The process according to claim 1 which is performed at a temperature between 2.degree. C. and 20.degree. C.

12. The process according to claim 1 which is performed at a temperature from 2.degree. C. to 8.degree. C.

13. The process according to claim 1 wherein the .alpha.-aztreonam comprises from 50 mg to 300 mg of anhydrous .alpha.-aztreonam and the lysine solution comprises from 35 mg to 420 mg of lysine monohydrate per 1 mL of water for injection.

14. The process according to claim 1 comprising manufacturing a bulk solution comprising about 75 mg/mL aztreonam lysinate.

15. The process according to claim 1 wherein the aztreonam lysinate bulk solution is lyophilized.

16. The process according to claim 15 wherein the aztreonam lysinate is suitable for aerosolization and is formulated in lyophilized dosage form.

17. The process according to claim 16 in which the aztreonam lysinate is further packaged in a package consisting of two separately packaged components, one component comprising a lyophilized aztreonam lysinate powder and the other component comprising a sterile saline diluent.

18. The process according to claim 17 wherein the sterile saline diluent is 0.1 to 0.9N saline.

19. A process for preparation of aztreonam lysinate for inhalation comprising manufacturing a bulk solution of aztreonam lysinate by addition of .alpha.-aztreonam to a lysine solution, wherein the bulk solution of aztreonam lysinate has a pH between 4.2 and 7 and the process is performed at a temperature between 2.degree. C. and 8.degree. C.

20. The process according to claim 19 comprising manufacturing a bulk solution comprising about 75 mg/mL aztreonam lysinate.

21. A process for preparation of aztreonam lysinate for inhalation comprising manufacturing a bulk solution of aztreonam lysinate by addition of a lysine solution to an .alpha.-aztreonam solution or slurry, wherein the bulk solution of aztreonam lysinate has a pH between 4.2 and 7 and the process is performed at a temperature between 2.degree. C. and 8.degree. C.

22. The process according to claim 21 comprising manufacturing a bulk solution comprising about 75 mg/mL aztreonam lysinate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc